The RNA silencer Wainua didn't improve outcomes for ATTR-CM patients who were already receiving the standard of care.

An arbitration panel ruled Prime did not violate an agreement with Beam when it developed PM647, for which Prime plans to launch a clinical trial.

The firm will use the proceeds to develop plixorafenib in BRAF-mutant brain tumors and possibly make a regulatory submission.

Current Chemolab equity holders will own approximately 32 percent of the combined company' shares and Scipher equity holders will own 68 percent.

The biotech is tackling common cardiovascular conditions by targeting risk factors like high cholesterol, triglycerides, and ...

The partnership will leverage Sanyou's AI-based libraries of over one trillion antibody gene sequences and Baiyunshan Xihe's supply chain expertise.

The deal involves non-dilutive cash in exchange for royalties, if the gene therapies are approved, and an equity investment from Oberland Capital.

The firm announced it has aligned with the US Food and Drug Administration on the design of the Phase III study, which could support a biologics license application.

Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...

The firm said it will use the funds to advance its KRAS-targeted cancer vaccine ELI-002 7P in KRAS-driven pancreatic cancer.

The gene therapy for multiple sulfatase deficiency was one of the preclinical programs the Bespoke Gene Therapy Consortium selected for its pilot.

Spur Therapeutics on Tuesday said it has treated the first Gaucher disease patient with its investigational gene therapy, FLT201 (avigbagene parvec), in a pivotal trial. In the Phase III GALILEO-3 ...